Company intelligence / Profile preview

Kainos Medicine, Inc.

Seongnam-si, Gyeonggi-do, South Koreakainosmedicine.com ↗

Ownership: Public · 284620
Development stage: Phase 2

Overview

Currently advancing Phase 2 clinical trials in the U.S. for KM-819 (Parkinson's disease treatment) and preparing to resume trials in Korea for multiple system atrophy (MSA) patients. Has completed Phase 1 clinical study for KM-819 for Parkinson's disease and has a Phase 3 clinical study product (KM023) for HIV/AIDS[5][6].

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

ainuovirine

2 more assets in the full pipeline.

Request access →

Partnerships

Emmaus Life Sciences, Inc. (for preclinical development of IRAK4 inhibitor)Chinese pharmaceutical company (for HIV/AIDS and anti-cancer agents)Adelphi Ventures

Beyond the preview

Go deeper on Kainos Medicine, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kainos Medicine, Inc..

Explore the full profile